证券代码：300573 证券简称：兴齐眼药 公告编号：2024-057 沈阳兴齐眼药股份有限公司 关于 2021 年限制性股票激励计划 第三个归属期归属结果暨股份上市公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次第二类限制性股票的归属日为 2024 年 11 月 11 日。 2、本次第二类限制性股票的归属数量为 824,376 股，占归属前公司总股本 的 0.47%，归属人数为 80 人。 3、本次第二类限制性股票上市流通日为 2024 年 11 月 11 日，本次归属的限 制性股票不设限售期。 沈阳兴齐眼药股份有限公司于 2024 年 10 月 16 日召开的第五届董事会第五 次会议及第五届监事会第五次会议审议通过了《关于公司 2021 年限制性股票激 励计划第三个归属期归属条件成就的议案》。近日，公司申请办理了 2021 年限制 性股票激励计划第三个归属期的登记工作，具体情况公告如下： 一、本次激励计划实施情况概要 （一）2021年限制性股票激励计划简介 公司分别于2021年8月26日召开的第四届董事会第五次会议及2021年 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to see accelerated growth in low-concentration atropine sales, with continuous improvement in its ophthalmic product offerings [4] - The company reported a revenue of 1.439 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 30.27% [4] - The net profit attributable to the parent company for the same period was 291 million yuan, up 59.47% year-on-year [4] - The gross margin for the first three quarters of 2024 was 78.38%, an increase of 0.80 percentage points [4] Financial Performance Summary - Revenue for 2024 is projected to be 2.058 billion yuan, with a year-on-year growth of 40.2% [6] - The net profit attributable to the parent company is expected to reach 440 million yuan in 2024, reflecting an 83.3% increase year-on-year [6] - The company maintains a high gross margin, projected at 79.7% for 2024 [6] - Earnings per share (EPS) is forecasted to be 2.52 yuan for 2024, with a significant increase in subsequent years [6] Product Development and Market Position - The company has established a comprehensive ophthalmic product line, including treatments for myopia progression and dry eye [5] - The low-concentration atropine eye drops have gained regulatory approval and are expected to capture significant market share due to the absence of similar products in the domestic market [5] - The company is actively promoting its products, anticipating rapid sales growth as the incidence of myopia increases [5]

Group 1: Market Position and Competition - The company has no direct competitors in the myopia drug treatment market, with three intervention methods available for children's myopia: behavioral, optical, and pharmacological [2] - The current market for children's myopia management includes approximately 82 million patients in China, with a need for increased awareness and treatment rates [2] Group 2: Sales and Marketing Strategy - The company employs an omnichannel sales strategy, including hospitals, pharmacies, e-commerce, and online healthcare platforms [2] - The gross margin and net margin for atropine are expected to improve as sales personnel are expanded and promotional expenses stabilize [2] Group 3: Product Development and Clinical Trials - The company announced on October 21, 2024, that the clinical trial for 0.02% and 0.04% atropine eye drops has completed its two-year administration phase and is entering the final year of the washout period [3] - The company plans to publish clinical trial results after the product launch [3] Group 4: Market Challenges and Growth - The overall pharmaceutical market has experienced slow growth, with the ophthalmic market showing a negative growth rate of -6.21% [4] - The company’s cyclosporine eye drops continue to maintain double-digit growth despite market challenges [4]

关于撤回药品注册申请的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-056 沈阳兴齐眼药股份有限公司 受理号：CYHS2300927 近日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的《药品注册申请终止通知书》，同 意公司撤回马来酸噻吗洛尔滴眼液的注册申请。现将相关情况公告如下： 药品名称：马来酸噻吗洛尔滴眼液 注册分类：化学药品 3 类 公司于 2023 年 3 月向国家药品监督管理局递交马来酸噻吗洛尔滴眼液仿制 药上市注册申请并获受理，申报适应症为：用于高眼压或开角型青光眼患者眼压 升高的治疗。受政策法规变更等因素影响，需进一步完善申报资料，经审慎研究， 公司决定主动撤回本次补充申请。 该药品注册申请的主动撤回并终止对已上市产品及公司研发工作无重大影 响，也不会对公司当期及未来生产经营与业绩产生重大影响。敬请广大投资者注 意投资风险。 特此公告。 沈阳兴齐眼药股份有限公司 董事会 2024 年 10 月 30 日 通知书编号： ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The report highlights significant cost reductions and the completion of the full follow-up study for atropine eye drops, which have shown significant efficacy in delaying myopia progression in children aged 6 to 12 years [2][3] - The company reported a revenue of 1.439 billion yuan for the past 12 months, representing a year-on-year increase of 30.27%, and a net profit attributable to shareholders of 291 million yuan, up 59.47% year-on-year [2] - The report anticipates revenue for 2024 to be 1.918 billion yuan, with a year-on-year growth of 30.7%, and net profit expected to reach 378 million yuan, reflecting a 57.7% increase [3][4] Financial Performance Summary - For Q3 2024, the company achieved a revenue of 547 million yuan, a year-on-year increase of 30.54%, and a net profit of 121 million yuan, up 28.41% year-on-year [2] - The gross profit margin for the first three quarters was 78.38%, an increase of 0.80 percentage points year-on-year, with a net operating cash flow of 356 million yuan, up 57.42% year-on-year [2][4] - The company has maintained a high dividend payout ratio, distributing 5.00 yuan per 10 shares, resulting in a dividend rate of 51.5% [2] Revenue and Profit Forecast - The projected revenues for 2024, 2025, and 2026 are 1.918 billion yuan, 2.820 billion yuan, and 3.650 billion yuan, respectively, with corresponding year-on-year growth rates of 30.7%, 47.0%, and 29.4% [3][4] - The net profit forecasts for the same years are 378 million yuan, 594 million yuan, and 790 million yuan, with year-on-year growth rates of 57.7%, 57.0%, and 33.1% [3][4] Key Financial Ratios - The company’s gross margin is expected to improve from 78.3% in 2024 to 79.9% in 2026, while the return on equity (ROE) is projected to rise from 23.2% in 2024 to 26.2% in 2026 [3][6] - The price-to-earnings (P/E) ratio is forecasted to decrease from 94.47 in 2024 to 21.52 in 2026, indicating an improving valuation as earnings grow [3][6]

Financial Performance - The company's operating revenue for Q3 2024 reached ¥547,493,493.82, representing a 30.54% increase compared to the same period last year[2]. - Net profit attributable to shareholders was ¥121,442,412.83, up 28.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥121,091,167.47, reflecting a 32.18% increase compared to the previous year[2]. - The basic and diluted earnings per share were both ¥0.70, a 29.63% increase from ¥0.54 in the same period last year[2]. - Total operating revenue for the current period reached ¥1,439,292,774.15, a 30.3% increase from ¥1,104,863,512.43 in the previous period[17]. - Net profit for the current period was ¥290,762,858.50, representing a 59.6% increase compared to ¥182,331,511.64 in the previous period[19]. - Basic and diluted earnings per share were both ¥1.67, up from ¥1.05 in the previous period[19]. - The company reported a total profit of ¥337,859,086.13, up from ¥202,691,425.08 in the previous period[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,185,769,518.15, an 8.00% increase from the previous year[3]. - The total liabilities increased to CNY 558,006,891.13 from CNY 333,923,878.75, reflecting a growth of approximately 67%[16]. - The company’s equity attributable to shareholders decreased to CNY 1,627,762,627.02 from CNY 1,689,920,857.47, a decline of about 3.7%[16]. - The company reported a total asset of CNY 2,185,769,518.15 as of September 30, 2024, an increase from CNY 2,023,844,736.22 at the beginning of the period, reflecting a growth of approximately 8%[14]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥355,665,775.92, a 57.42% increase compared to the same period last year[6]. - Cash inflow from operating activities totaled ¥1,439,784,095.73, an increase from ¥1,059,437,010.02 in the previous period[20]. - The net cash flow from operating activities for Q3 2024 was CNY 355,665,775.92, an increase of 57.5% compared to CNY 225,936,626.98 in Q3 2023[21]. - The ending balance of cash and cash equivalents was CNY 503,308,315.77, up from CNY 425,355,427.88 at the end of Q3 2023, reflecting an increase of 18.3%[21]. - Cash inflow from financing activities amounted to CNY 234,207,278.57, significantly up from CNY 72,515,217.20 in Q3 2023, representing an increase of 223.5%[21]. - The net cash flow from financing activities was -CNY 218,598,586.24, worsening from -CNY 120,914,243.87 year-over-year[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,554, with a holding ratio of 28.60% for domestic individuals[7]. - Liu Jidong holds 12,473,195 shares, representing a significant portion of the company's equity[8]. - The top ten shareholders account for a total of 38.60% of the company's shares, indicating a concentrated ownership structure[9]. - The total number of shares held by the top ten unrestricted shareholders is 28,060,000, indicating a healthy liquidity position[9]. - The total number of shares held by the top ten unrestricted shareholders represents 22.50% of the total share capital, highlighting their influence on corporate governance[9]. Research and Development - The company successfully obtained drug registration certificates for two products, including atropine sulfate eye drops and bromfenac sodium eye drops, enhancing its product portfolio[12]. - The company initiated the first subject enrollment for the Phase I clinical trial of SQ-22031 eye drops, marking a significant step in its R&D efforts[13]. - Research and development expenses rose to ¥139,482,476.89, compared to ¥121,550,678.54 in the previous period, indicating a focus on innovation[17]. Other Financial Metrics - The company reported a significant increase in other income, which rose by 89.79% to ¥26,662,744.62 due to increased government subsidies[6]. - The company experienced a decrease in credit impairment losses, which were reported at -¥3,267,560.09, an improvement from -¥4,359,935.51 in the previous period[18]. - The company reported a significant increase in inventory, which rose to CNY 145,089,102.76 from CNY 136,025,273.52, an increase of approximately 6.5%[14]. - The company’s non-current assets totaled CNY 1,238,106,586.80, up from CNY 1,118,656,222.40, indicating a growth of about 10.7%[15].

兴齐眼药：撤回盐酸丙美卡因滴眼液的注册申请 财联社10月22日电，兴齐眼药公告，近日，公司收到 国家药监局核准签发的《药品注册申请终止通知书》，同意公司撤回盐酸丙美卡因滴眼液的注册申请。 公司于2023年12月向国家药监局递交盐酸丙美卡因滴眼液仿制药上市注册申请并获受理，申报适应症 为：用于眼科局部麻醉。 受政策法规变更等因素影响，结合市场注册申报情况及公司研发策略，经审慎研究，公司决定主动撤回 该注册申请。 该药品注册申请的主动撤回并终止对公司研发工作无重大影响，也不会对公司当期及未来生产经营与业 绩产生重大影响。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-054 沈阳兴齐眼药股份有限公司 关于撤回药品注册申请的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 通知书编号：2024L00402 审查结论：根据《药品注册管理办法》第八十九条以及申请人的撤回申请， 同意本品注册申请撤回，终止注册程序。 公司于 2023 年 12 月向国家药品监督管理局递交盐酸丙美卡因滴眼液仿制 药上市注册申请并获受理，申报适应症为：用于眼科局部麻醉。受政策法规变更 等因素影响，结合市场注册申报情况及公司研发策略，经审慎研究，公司决定主 动撤回该注册申请。 该药品注册申请的主动撤回并终止对公司研发工作无重大影响，也不会对公 司当期及未来生产经营与业绩产生重大影响。敬请广大投资者注意投资风险。 特此公告。 沈阳兴齐眼药股份有限公司 近日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的《药品注册申请终止通知书》，同 意公司撤回盐酸丙美卡因滴眼液的注册申请。现将相关情况公告如下： 药品名称：盐酸丙美卡因滴眼液 注册分 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-053 沈阳兴齐眼药股份有限公司 关于硫酸阿托品滴眼液（0.01%）延缓儿童近视进展的 2 年临床试验 取得Ⅲ期临床试验总结报告的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的硫酸阿托品滴眼液， 近日获得了"硫酸阿托品滴眼液延缓儿童近视进展的有效性和安全性的随机、双 盲、安慰剂平行对照、多中心 2 年临床试验"临床总结报告。根据《深圳证券交 易所上市公司自律监管指引第 4 号——创业板行业信息披露》的有关规定，现将 主要内容公告如下： 一、基本情况 药品名称：硫酸阿托品滴眼液 剂型：滴眼剂 注册分类：本品按照化学药品 3 类路径申报 适应症：本品用于延缓球镜度数为-1.00D 至-4.00D（散光≤1.50D、屈光参差 ≤1.50D）的 6 至 12 岁儿童的近视进展。 临床申请受理号：CXHL1800178 临床试验分期：Ⅲ期临床试验 申办方：沈阳兴齐眼药股份有限公司 研究组长单位：温州医科大学附属眼视光医院 二、同类药品市场状况 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-052 沈阳兴齐眼药股份有限公司 关于硫酸阿托品滴眼液（0.02%/0.04%）延缓儿童近视进展的 临床试验取得Ⅲ期临床试验总结报告的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的硫酸阿托品滴眼液， 近日获得了"不同浓度硫酸阿托品滴眼液（0.02%/0.04%）延缓儿童近视进展的 有效性和安全性的随机、双盲、安慰剂平行对照、多中心 III 期临床试验"临床 总结报告。根据《深圳证券交易所上市公司自律监管指引第 4 号——创业板行业 信息披露》的有关规定，现将主要内容公告如下： 一、基本情况 药品名称：硫酸阿托品滴眼液 剂型：滴眼剂 注册分类：化学药品 2.4 类 适应症：延缓儿童近视进展。 临床申请受理号：CXHL2101085、CXHL2101086 临床试验分期：Ⅲ期临床试验 研究方法：随机、双盲、安慰剂平行对照、多中心的临床试验 申办方：沈阳兴齐眼药股份有限公司 研究组长单位：首都医科大学附属北京同仁医院 二、同类药品市场状况 ...